Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene Lab has the Profitability Rank of 2. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:
1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
BioNexus Gene Lab Profitability Rank Related Terms
BGLC vs VYST, QGAI, CNEY: Profitability Rank Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Profitability Rank vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Profitability Rank distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
BioNexus Gene Lab has the Profitability Rank of 2. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a Profitability Rank of 2 as of Jun. 2026. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on BioNexus Gene Lab and its competitors. This is 50% below median its historical median of 4.00. Over the past decade, BioNexus Gene Lab's Profitability Rank has ranged from 1.00 to 5.00.
Is BioNexus Gene Lab's Profitability Rank too high?
BioNexus Gene Lab's current Profitability Rank of 2 is 50% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. Overall, BioNexus Gene Lab has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Profitability Rank compare to VYST and QGAI?
BioNexus Gene Lab's Profitability Rank of 2 can be compared against companies in the Chemicals industry. Historically, BioNexus Gene Lab's own Profitability Rank has ranged from 1.00 to 5.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Profitability Rank for a Chemicals company?
A good Profitability Rank depends on the Chemicals industry context. However, Profitability Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Profitability Rank mean?
A high Profitability Rank can signal that a stock is expensive relative to its fundamentals. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on BioNexus Gene Lab and its competitors. BioNexus Gene Lab's current Profitability Rank is 2, which is 50% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $1.50 — trading 20% above its estimated fair value. The current Profitability Rank is 2, which is 50% below median its 10-year median of 4.00. BioNexus Gene Lab's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Profitability Rank calculated?
Profitability Rank is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Profitability Rank is 2 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be overvalued.
The current stock price of $1.50 is trading 20% above its estimated GF Value™ of $1.25.
GuruFocus considers BioNexus Gene Lab to be Modestly Overvalued.
Key valuation signals for BGLC:
Profitability Rank: 2 (50% below median its 10-year median of 4.00)
GF Value™: $1.25 vs. price of $1.50 (20% above fair value)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
56GF Score
Get the complete analysis for BGLC
Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
